{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:40:50Z","timestamp":1792636850343,"version":"4.5.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Objective of this study is to quantify benefit-risk tradeoffs pertaining to potential gene therapies among adults and parents\/caregivers of children with sickle cell disease (SCD). A discrete-choice experiment survey was developed in which respondents selected their preferred treatment alternatives in a series of experimentally controlled pairs of hypothetical gene therapies and a \u201cno gene therapy\u201d option. Gene therapy alternatives were defined based on the chance of eliminating SCD symptoms, expected increases in life expectancy they could offer, treatment-related risk of death, and potential increases in lifetime cancer risk. Respondents made selections based on their current disease severity and in the context of expectations of worsened disease. Three clinical sites and 1 patient organization recruited 174 adult patients and 109 parents of children with SCD to complete the survey. Adult and parent respondents were generally willing to choose gene therapies, but the adults required higher expected levels of efficacy (ie, higher chance of eliminating symptoms) than parents to choose gene therapies that conferred mortality risks of \u226510%. When adults and parents of children with less severe symptoms were asked to consider scenarios of higher levels of disease severity, the increased risk tolerance, and the lowest acceptable level of efficacy for gene therapies with mortality risks dropped by &amp;gt;50%. Baseline SCD symptoms are a major driver of gene therapy acceptability. Adults and parents of patients with milder symptoms may prefer other treatment options; however, an expectation of symptoms deterioration triggers strong reassessment of the acceptable benefit-risk balance of this novel technology.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023009680","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T09:51:16Z","timestamp":1698745876000},"page":"7371-7381","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Preferences for potential benefits and risks for gene therapy in the treatment of sickle cell disease"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5386-0907","authenticated-orcid":false,"given":"Juan Marcos","family":"Gonzalez Sepulveda","sequence":"first","affiliation":[{"name":"1Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Chen","family":"Yang","sequence":"additional","affiliation":[{"name":"2Duke Clinical Research Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby D.","family":"Reed","sequence":"additional","affiliation":[{"name":"1Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Hsuan","family":"Lee","sequence":"additional","affiliation":[{"name":"3Center for Biologics Evaluation and Research, Office of Biostatistics and Pharmacovigilance, US Food and Drug Administration, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Ng","sequence":"additional","affiliation":[{"name":"3Center for Biologics Evaluation and Research, Office of Biostatistics and Pharmacovigilance, US Food and Drug Administration, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Stothers","sequence":"additional","affiliation":[{"name":"3Center for Biologics Evaluation and Research, Office of Biostatistics and Pharmacovigilance, US Food and Drug Administration, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Telba","family":"Irony","sequence":"additional","affiliation":[{"name":"3Center for Biologics Evaluation and Research, Office of Biostatistics and Pharmacovigilance, US Food and Drug Administration, Rockville, MD"},{"name":"4Janssen Research & Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ho","sequence":"additional","affiliation":[{"name":"3Center for Biologics Evaluation and Research, Office of Biostatistics and Pharmacovigilance, US Food and Drug Administration, Rockville, MD"},{"name":"5Pfizer, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-2886","authenticated-orcid":false,"given":"Jennifer A.","family":"Rothman","sequence":"additional","affiliation":[{"name":"1Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Badawy","sequence":"additional","affiliation":[{"name":"6Lurie Children\u2019s Hospital of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Rowley","sequence":"additional","affiliation":[{"name":"7Cayenne Wellness Center, Burbank, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Little","sequence":"additional","affiliation":[{"name":"8Division of Hematology, The University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7506-0935","authenticated-orcid":false,"given":"Nirmish R.","family":"Shah","sequence":"additional","affiliation":[{"name":"1Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwen","family":"Li","sequence":"additional","affiliation":[{"name":"1Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3809-1780","authenticated-orcid":false,"given":"Marilyn J.","family":"Telen","sequence":"additional","affiliation":[{"name":"1Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"issue":"11","key":"2023121216230909400_bib1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJM199709113371107","article-title":"Pathogenesis and treatment of sickle cell disease","volume":"337","author":"Bunn","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"2023121216230909400_bib2","unstructured":"Centers for Disease Control and Prevention\n              \n            \n          . Data & Statistics on Sickle Cell Disease. Accessed 8 December 2021. https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.html."},{"issue":"7","key":"2023121216230909400_bib3","doi-asserted-by":"crossref","first-page":"e1001484","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med"},{"issue":"6","key":"2023121216230909400_bib4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bull World Health Organ"},{"key":"2023121216230909400_bib5","unstructured":"American Society of Hematology\n          . State of Sickle Cell Disease 2016 Report. 2016. Accessed 8 December 2021. http:\/\/www.scdcoalition.org\/pdfs\/ASH%20State%20of%20Sickle%20Cell%20Disease%202016%20Report.pdf."},{"key":"2023121216230909400_bib6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3389\/fphys.2020.00435","article-title":"Recent advances in the treatment of sickle cell disease","volume":"11","author":"Salinas Cisneros","year":"2020","journal-title":"Front Physiol"},{"issue":"4","key":"2023121216230909400_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.hemonc.2017.05.008","article-title":"Hematopoietic stem cell transplantation for sickle cell disease: the changing landscape","volume":"10","author":"Kassim","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"2","key":"2023121216230909400_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bbmt.2015.10.017","article-title":"Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease","volume":"22","author":"Walters","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023121216230909400_bib9","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/bjh.16437","article-title":"Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?","volume":"189","author":"Leonard","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"2023121216230909400_bib10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood-2015-09-618587","article-title":"Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease","volume":"127","author":"Hoban","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2023121216230909400_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/MOH.0000000000000581","article-title":"Current and future gene therapies for hemoglobinopathies","volume":"27","author":"Brendel","year":"2020","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"2023121216230909400_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bjh.16504","article-title":"Emerging therapies in sickle cell disease","volume":"190","author":"Nardo-Marino","year":"2020","journal-title":"Br J Haematol"},{"issue":"18 suppl","key":"2023121216230909400_bib13","first-page":"S335","article-title":"Sickle cell disease: current treatment and emerging therapies","volume":"25","author":"Neumayr","year":"2019","journal-title":"Am J Manag Care"},{"issue":"11","key":"2023121216230909400_bib14","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1182\/blood.2019003776","article-title":"Gene therapy for sickle cell disease: moving from the bench to the bedside","volume":"138","author":"Abraham","year":"2021","journal-title":"Blood"},{"key":"2023121216230909400_bib15","unstructured":"U.S. Food and Drug Administration\n          . Benefit-Risk Assessment for New Drug and Biological Products Guidance for Industry - Draft Guidance. Accessed 8 December 2021. https:\/\/www.fda.gov\/media\/152544\/download."},{"key":"2023121216230909400_bib16","unstructured":"U.S. Food and Drug Administration\n          . Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications - Guidance for Industry and Food and Drug Administration Staff. Accessed 8 December 2021. https:\/\/www.fda.gov\/media\/99769\/download."},{"key":"2023121216230909400_bib17","unstructured":"U.S. Food and Drug Administration\n          . Patient Preference Information \u2013 Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. Accessed 8 December 2021. https:\/\/www.fda.gov\/media\/92593\/download."},{"issue":"8","key":"2023121216230909400_bib18","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1007\/s12325-017-0587-7","article-title":"Patient perspectives on gene transfer therapy for sickle cell disease","volume":"34","author":"Strong","year":"2017","journal-title":"Adv Ther"},{"issue":"1-2","key":"2023121216230909400_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1089\/hum.2019.197","article-title":"Public acceptability of gene therapy and gene editing for human use: a systematic review","volume":"31","author":"Delhove","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"4","key":"2023121216230909400_bib20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"issue":"1","key":"2023121216230909400_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","article-title":"Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force","volume":"16","author":"Reed Johnson","year":"2013","journal-title":"Value Health"},{"issue":"4","key":"2023121216230909400_bib22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"key":"2023121216230909400_bib23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2147\/CEOR.S276121","article-title":"Development of a severity classification system for sickle cell disease","volume":"12","author":"Shah","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"key":"2023121216230909400_bib24","author":"Kuhfeld","year":"2010"},{"key":"2023121216230909400_bib25","author":"Hole","year":"2009"},{"issue":"3","key":"2023121216230909400_bib26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40271-019-00360-3","article-title":"A\u00a0guide to measuring and interpreting attribute importance","volume":"12","author":"Gonzalez","year":"2019","journal-title":"Patient"},{"issue":"4","key":"2023121216230909400_bib27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2307\/1924536","article-title":"On approximating the statistical properties of elasticities","volume":"68","author":"Krinsky","year":"1986","journal-title":"Rev Econ Stat"},{"issue":"2","key":"2023121216230909400_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jval.2018.07.876","article-title":"The internal validity of discrete choice experiment data: a testing tool for quantitative assessments","volume":"22","author":"Johnson","year":"2019","journal-title":"Value Health"},{"issue":"3","key":"2023121216230909400_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0268-960X(03)00006-7","article-title":"Hematopoietic stem cell transplantation in sickle cell disease","volume":"17","author":"Vermylen","year":"2003","journal-title":"Blood Rev"},{"issue":"19","key":"2023121216230909400_bib30","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199111073251905","article-title":"Bone marrow transplantation for sickle cell disease: a study of parents' decisions","volume":"325","author":"Kodish","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023121216230909400_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/hae.14278","article-title":"Evidence of a disability paradox in patient-reported outcomes in haemophilia","volume":"27","author":"O\u2019Hara","year":"2021","journal-title":"Haemophilia"},{"key":"2023121216230909400_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.vhri.2015.03.016","article-title":"Comparing patient and physician risk tolerance for bleeding events associated with anticoagulants in atrial fibrillation\u2014evidence from the United States and Japan","volume":"6","author":"Okumura","year":"2015","journal-title":"Value Health Reg Issues"},{"issue":"3","key":"2023121216230909400_bib33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40271-017-0295-z","article-title":"Evaluating risk tolerance from a systematic review of preferences: the case of patients with psoriasis","volume":"11","author":"Gonzalez","year":"2018","journal-title":"Patient"},{"key":"2023121216230909400_bib34","author":"Society","year":"2014"},{"issue":"3S","key":"2023121216230909400_bib35","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.annemergmed.2020.08.009","article-title":"Trends in sickle cell disease\u2013related mortality in the United States, 1979 to 2017","volume":"76","author":"Payne","year":"2020","journal-title":"Ann Emerg Med"},{"issue":"9","key":"2023121216230909400_bib36","first-page":"2318","article-title":"Fertility after curative therapy for sickle cell disease: a comprehensive review to guide care","volume":"11","author":"Nickel","year":"2022","journal-title":"J\u00a0Clin Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/23\/7371\/2176280\/blooda_adv-2023-009680-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/23\/7371\/2176280\/blooda_adv-2023-009680-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T11:30:20Z","timestamp":1702380620000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/23\/7371\/498529\/Preferences-for-potential-benefits-and-risks-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":36,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023,12,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023009680","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]}}}